Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)
Identifieur interne : 002840 ( Main/Exploration ); précédent : 002839; suivant : 002841Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)
Auteurs : I. Shoulson [États-Unis]Source :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 1989-11.
English descriptors
- KwdEn :
Abstract
Abstract– DATATOP is a double‐blind, multi‐center, placebo‐controlled clinical trial aimed at slowing the decline of patients who are in the early stages of Parkinson's disease (PD). The specific aim is to determine whether or not chronic administration of deprenyl 10 mg per day and/or tocopherol 2000 IU per day to early, otherwise untreated PD patients will prolong the time until levodopa therapy is required to treat emerging disability. Deprenyl and tocopherol exert antioxidative effects through separate but complementary mechanisms of action. A 2 X 2 factorial design allocates eligible subjects to one of four treatment groups: 1) deprenyl alone, 2) tocopherol alone, 3) deprenyl plus tocopherol, or 4) placebo. Eligible subjects include early PD patients (illness duration less than 5 years and in stages I and II), aged 30 to 79, who are not taking or requiring any anti‐PD medications. The major response variable is the time period from randomization until the blinded investigator judges levodopa necessary to treat emerging parkinsonian disability. Randomization is stratified to ensure that treatment assignments are balanced for each blinded investigator. Cerebrospinal fluid is sampled just prior to randomization and one month after washout of experimental medications in order to help distinguish between symptomatic and protective effects of interventions. Based on pilot studies it is estimated that approximately 85 % of untreated PD patients will require levodopa within two years and a total sample size of 800 subjects will provide a 95 % likelihood for detecting a 10 %“survival'’difference between experimental medications and placebo. Between September 1987 and November 1988, 800 eligible subjects were enrolled in DATATOP by 34 investigators of the Parkinson Study Group, representing research centers in the United States and Canada. Primary analyses of DATATOP should be completed in 1991.
Url:
DOI: 10.1111/j.1600-0404.1989.tb01798.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)</title><author><name sortKey="Shoulson, I" sort="Shoulson, I" uniqKey="Shoulson I" first="I." last="Shoulson">I. Shoulson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:79062544A2AE653E90A759BDAFC71EE384E96749</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1111/j.1600-0404.1989.tb01798.x</idno><idno type="url">https://api.istex.fr/document/79062544A2AE653E90A759BDAFC71EE384E96749/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000593</idno><idno type="wicri:Area/Main/Curation">000517</idno><idno type="wicri:Area/Main/Exploration">002840</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)</title><author><name sortKey="Shoulson, I" sort="Shoulson, I" uniqKey="Shoulson I" first="I." last="Shoulson">I. Shoulson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>the Parkinson Study Group, Department of Neurology, University of Rochester Medical Center, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neurologica Scandinavica</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1989-11">1989-11</date><biblScope unit="volume">80</biblScope><biblScope unit="supplement">s126</biblScope><biblScope unit="page" from="171">171</biblScope><biblScope unit="page" to="175">175</biblScope></imprint><idno type="ISSN">0001-6314</idno></series><idno type="istex">79062544A2AE653E90A759BDAFC71EE384E96749</idno><idno type="DOI">10.1111/j.1600-0404.1989.tb01798.x</idno><idno type="ArticleID">ANE171</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>clinical trial</term><term>deprenyl</term><term>experimental therapeutics</term><term>protective therapy</term><term>tocopherol</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract– DATATOP is a double‐blind, multi‐center, placebo‐controlled clinical trial aimed at slowing the decline of patients who are in the early stages of Parkinson's disease (PD). The specific aim is to determine whether or not chronic administration of deprenyl 10 mg per day and/or tocopherol 2000 IU per day to early, otherwise untreated PD patients will prolong the time until levodopa therapy is required to treat emerging disability. Deprenyl and tocopherol exert antioxidative effects through separate but complementary mechanisms of action. A 2 X 2 factorial design allocates eligible subjects to one of four treatment groups: 1) deprenyl alone, 2) tocopherol alone, 3) deprenyl plus tocopherol, or 4) placebo. Eligible subjects include early PD patients (illness duration less than 5 years and in stages I and II), aged 30 to 79, who are not taking or requiring any anti‐PD medications. The major response variable is the time period from randomization until the blinded investigator judges levodopa necessary to treat emerging parkinsonian disability. Randomization is stratified to ensure that treatment assignments are balanced for each blinded investigator. Cerebrospinal fluid is sampled just prior to randomization and one month after washout of experimental medications in order to help distinguish between symptomatic and protective effects of interventions. Based on pilot studies it is estimated that approximately 85 % of untreated PD patients will require levodopa within two years and a total sample size of 800 subjects will provide a 95 % likelihood for detecting a 10 %“survival'’difference between experimental medications and placebo. Between September 1987 and November 1988, 800 eligible subjects were enrolled in DATATOP by 34 investigators of the Parkinson Study Group, representing research centers in the United States and Canada. Primary analyses of DATATOP should be completed in 1991.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Shoulson, I" sort="Shoulson, I" uniqKey="Shoulson I" first="I." last="Shoulson">I. Shoulson</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002840 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002840 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:79062544A2AE653E90A759BDAFC71EE384E96749
|texte= Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)
}}
| This area was generated with Dilib version V0.6.23. |  |